JPMorgan Cuts Medline Price Target
The price target for Medline (NASDAQ:MDLN) was cut to $46.00 by analysts at JPMorgan Chase & Co.
This reduction comes after a series of revisions from other brokerages, including Barclays and Sanford C. Bernstein.
Despite the downward adjustment, Medline's stock has a consensus rating of 'Moderate Buy' with an average price target of $47.42.